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Polymorphisms in the interleukin-4 receptor  chain (IL-4R) have been linked to asthma
incidence and severity, but a causal relationship has remained uncertain. In particular, a
glutamine to arginine substitution at position 576 (Q576R) of IL-4R has been associated
with severe asthma, especially in African Americans. We show that mice carrying the Q576R
polymorphism exhibited intense allergen-induced airway inflammation and remodeling. The
Q576R polymorphism did not affect proximal signal transducer and activator of transcription
(STAT) 6 activation, but synergized with STAT6 in a gene target– and tissue-specific manner
to mediate heightened expression of a subset of IL-4– and IL-13–responsive genes involved
in allergic inflammation. Our findings indicate that the Q576R polymorphism directly promotes asthma in carrier populations by selectively augmenting IL-4R–dependent signaling.
CORRESPONDENCE
Talal A. Chatila:
Tchatila@mednet.ucla.edu
Abbreviations used: AHR,
airway hyperresponsiveness;
ANOVA, analysis of variance;
BAL, bronchoalveolar lavage;
BMDM, bone marrow–derived
macrophage; ES, embryonic
stem; Het, heterozygote; ITIM,
immunoreceptor tyrosine-based
inhibitory motif; MAPK, mitogen-activated protein kinase;
MBP1, major basic protein 1;
PAS, periodic acid–Schiff; PI3,
phosphatidylinositol 3; TEC,
tracheal airway epithelial cell.

Asthma is an obstructive airway disease that
affects an unusually large segment of the population and results in significant morbidity, and at
times mortality. It is well appreciated that predisposition to asthma is genetically determined,
whereas its clinical expression is controlled by
environmental factors (Gern et al., 1999). Genes
of the IL-4–IL-13–IL-4R cytokine pathway
have been identified as leading candidates in
conferring susceptibility to asthma (Ober and
Hoffjan, 2006). These functionally overlapping
cytokines are key effectors of Th2-dependent
responses, including stimulation of IgE synthesis, modulation of lymphocyte and antigenpresenting cell function, and induction of allergic
inflammation. In the allergen-exposed airway,
this inflammatory response involves recruitment
of eosinophils, mucin hypersecretion, generation of airway hyperresponsiveness (AHR), and,
eventually, airway remodeling, characterized by
subepithelial fibrosis, neovascularization, and other
permanent alterations in airway microanatomy
(Elias et al., 1999).
IL-4 and IL-13 share a common receptor
component, the IL-4R chain, that pairs with
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distinct subunits (Nelms et al., 1999; Hershey,
2003; Chatila, 2004). IL-4R pairs with the
common c chain to form a type I IL-4R complex that is found predominantly in hematopoietic cells and is exclusive for IL-4. IL-4R also
pairs with the IL-13R1 subunit to form a type
II IL-4R that binds both IL-4 and IL-13. The
type II receptor is expressed on both hematopoietic and nonhematopoietic cells such as
airway epithelium. IL-4 and IL-13 activate receptor-associated Janus kinases, which initiate
several intracellular signaling cascades by phosphorylating specific tyrosine (Y) residues in the
cytoplasmic domain of IL-4R (Nelms et al.,
1999; Hershey, 2003; Chatila, 2004). Phosphorylation of Y575, Y603, and Y633 of human IL-4R mobilizes the transcription factor
STAT6, which induces IL-4– and IL-13–
responsive genes. Additional cell growth and
regulatory functions are served by Y497, which
© 2009 Tachdjian et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.jem.org/misc/terms.shtml). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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RESULTS
Generation of IL-4RR576 mutant mice by targeted
knock-in mutagenesis
To elucidate the impact of the human Q576R polymorphism
on IL-4R function, we adopted a genetic approach that took
advantage of the conservation of the Q576 motif (peptide sequence 574-GYQEFG-579) in mouse and human to substitute the equivalent glutamine residue of the mouse receptor
(also Q576) with arginine. A targeting construct was designed
to replace exon 12 of Il4ra of embryonic stem (ES) cells with
another bearing AG→GA substitutions at the second and
third positions of the Q576 codon that changed the codon
specificity to R576 (Fig. S1 A; Wrighton et al., 1992). Successfully targeted ES clones were used to derive mouse male
chimera that transmitted the R576 mutation into the germline
2192

(Fig. S1 B). Matings of IL-4R heterozygotes (Hets) resulted
in generation of R576 homozygous mutant mice in numbers
consistent with Mendelian inheritance. Homozygous mutant
mice of both sexes were phenotypically indistinguishable from
their WT and Het littermates. The transmission and integrity
of the mutant allele was verified by several methods, including
Southern blot analysis, allele-specific PCR amplification, and
direct sequencing of genomic DNA (Fig. S1, B–D; and not
depicted). Expression of mutant receptor protein was verified
by flow cytometry to be closely matched to WT controls
(Fig. S1 E). Analysis revealed the T and B lymphocytes of the
IL-4R R576 mutant mice to be normal in number and phenotype (unpublished data).
The R576 allele promotes antigen-induced allergic
airway inflammation and remodeling
The functional consequences of the R576 mutation were
analyzed in antigen-driven mouse models of allergic airway
inflammation. In an acute model of allergic airway inflammation, C.129.Il4ra R576/R576 and C.129.Il4ra Q576/Q576 mice were
i.p. sensitized and boosted with OVA in alum, and challenged
at 4 wk after sensitization with inhaled OVA for three consecutive days. Control mice were immunized and boosted
with PBS/alum and challenged with inhaled OVA. Examination of lung tissue of WT and mutant mice stained with
hematoxylin and eosin (H&E) revealed patchy peribronchial
inflammatory infiltrates, composed primarily of eosinophils
and lymphocytes, that were substantially more prominent
in OVA-sensitized and -challenged C.129.Il4ra R576/R576 mice
as compared with C.129.Il4ra Q576/Q576 controls (Fig. 1 A).
In contrast, sham-immunized mice exposed to aerosolized
OVA showed normal lung histology (unpublished data).
Significantly, OVA-challenged C.129.Il4ra R576/R576 mutants
exhibited markedly increased peribronchial and perivascular inflammation and increased numbers of goblet cells compared with C.129.Il4ra Q576/Q576 controls (Fig. 1, B and C;
Grünig et al., 1998; Wills-Karp et al., 1998; Dabbagh et al.,
1999; Kuperman et al., 2002). Analysis of bronchoalveolar
lavage (BAL) fluid of OVA-sensitized and -challenged mice
revealed that C.129.Il4ra R576/R576 mice exhibited increased
accumulation of eosinophils in the airways as compared with
similarly treated controls (Fig. 1 D). These results indicated
that the R576 substitution caused an increase in the airway
inflammatory response to allergen.
We next examined the impact of the R576 mutation on
airway inflammation and remodeling in chronic OVA-driven
allergic airway inflammation (Wegmann et al., 2005). This
model better reflects some of the physiological changes
associated with chronic asthma, including subepithelial
fibrosis. Accordingly, C.129.Il4ra R576/R576 and control
C.129.Il4ra Q576/Q576 mice were sensitized and boosted with
OVA in alum, and starting at week 4 after sensitization they
were challenged with OVA by inhalation twice daily for an
additional 8 wk (Wegmann et al., 2005). Histological analy
sis revealed that the C.129.Il4ra R576/R576 mice exhibited
increased perivascular inflammation and tissue eosinophilia
IL4RA ALLELES IN ASTHMA PATHOGENESIS | Tachdjian et al.
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activates phosphatidylinositol 3 (PI3)–kinase and mitogena ctivated protein kinase (MAPK) pathways, and by an immuno
receptor tyrosine-based inhibitory motif (ITIM) at Y713 that
activates phosphotyrosine and inositol phosphatases.
An essential role for IL-4R signaling in asthma pathogenesis has been established (Chatila, 2004). Increased expression of IL-13 and, to a lesser extent, IL-4 in mouse airways
reproduces many of the pathophysiological changes that are
typical of asthma (Elias et al., 1999). Blockade of IL-13 or deletion of IL-4R or STAT6 genes renders mice resistant to
the induction of experimental allergic asthma (Grünig et al.,
1998; Wills-Karp et al., 1998). IL-4R chain expression in
resident airway tissues is required for development of allergic
airway inflammation upon antigen exposure. Induction of
AHR, goblet cell metaplasia, and mucin overproduction have
been found to be dependent on IL-4R signaling in airway
epithelial cells (Kuperman et al., 2002). Furthermore, coding
genetic polymorphisms in the human IL-4R chain gene
have been implicated in susceptibility to both atopy and
asthma (Hershey et al., 1997; Ober et al., 2000; Howard et al.,
2002). Of particular interest is the Q576R polymorphism that
is associated with asthma susceptibility in outbred populations,
especially severe asthma (Hershey et al., 1997; Rosa-Rosa
et al., 1999; Ober et al., 2000; Sandford et al., 2000; Wenzel
et al., 2007). The Q576R polymorphism has also been linked
to severe respiratory syncytial virus–induced bronchiolitis
(Hoebee et al., 2003), rapid decline in lung function in smokers (He et al., 2003), and heightened allergen sensitization in
the context of maternal smoking (Liu et al., 2004). Of interest, this allele is overrepresented in the African-American
population (70% allele frequency in African Americans vs.
20% in Caucasians, giving rise to 50 and 4% homozygosity,
respectively; Caggana et al., 1999; Ober et al., 2000; Wu
et al., 2001; Akinbami and Schoendorf, 2002; Mannino et al.,
2002). In concert with increased frequency of the Q576R
polymorphism, African Americans suffer from heightened
asthma prevalence and severity. To address the role of the
Q576R polymorphism in allergic airway inflammation, we
have developed a mouse model in which the Q576 residue,
which is conserved in mice, is changed to R576.
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as compared with control mice (Fig. 2, A–E, arrows in
B and D). Sirius red staining revealed markedly increased
subepithelial collagen deposition in the mutant mice as
compared with controls (Fig. 2, F–J). These findings indicated that the R576 mutation exacerbated chronic sequelae
of airway inflammation, such as airway remodeling, that are
key determinants of disease morbidity in asthma.
The R576 allele promotes IL-13–induced allergic
airway inflammation
Many aspects of antigen-induced allergic airway inflammation, including AHR, eosinophilic infiltration, goblet cell
metaplasia, and tissue remodeling, can be induced by the
direct action of IL-13 on resident airway tissue independent
of the adaptive immune response. To determine whether

Downloaded from jem.rupress.org on September 13, 2011

Figure 1. The Q576R substitution promotes acute antigeninduced allergic airway inflammation. OVA-sensitized C.129.Il4ra Q576/Q576
(Q576) and C.129.Il4ra R576/R576 (R576) mice (n = 13 and 11, respectively)
were challenged intranasally with OVA on three consecutive days and
analyzed. (A) Lung histology (PAS staining). (B) Semiquantitative analysis
of the severity of peribronchial inflammation represented by the mean of
the inflammation scores, as described in Materials and methods. (C) Enumeration of PAS-positive goblet cells in the airways. (D) BAL fluid analysis
for inflammatory cells. Values represent means ± SEM derived from two
independent experiments. *, P < 0.05; **, P < 0.01. Bar, 200 µm.
JEM VOL. 206, September 28, 2009

Figure 2. The Q576R substitution promotes airway inflammation
and remodeling after chronic allergen challenge. (A–E) Sham- (PBS)
and OVA-sensitized C.129.Il4ra Q576/Q576 and C.129.Il4ra R576/R576 mice (n =
15–20 per group) were challenged intranasally with PBS and OVA, respectively, twice weekly for 12 wk. Airway inflammation was analyzed by histology (H&E staining; A–D), and inflammatory cells in the lung
parenchyma were enumerated (E). Arrows in B and D represent areas of
perivascular infiltration. (F–J) Detection (F–I) and quantitation (J) of subepithelial collagen deposition by Sirius red staining. Values represent
means ± SEM of results from 8–10 mice derived from two independent
experiments. HPF, high power field. *, P < 0.05; **, P < 0.01. Bars, 100 µm.
2193
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eosinophilia as compared with the B6.Il4raQ576/Q576/IL-13tg
single-transgenic mice, and this difference was further amplified upon doxycycline induction of IL-13 (Fig. 4 A). Although the single- and double-transgenic mice exhibited
equivalent percentages of goblet cells at baseline, the
B6.129Il4raR576/R576/IL-13tg double-transgenic mice were
more responsive to doxycycline treatment. While the percentage of goblet cells doubled upon doxycycline treatment
of IL-13tg single-transgenic mice, it nearly quadrupled in
the similarly treated B6.129Il4raR576/R576/IL-13tg doubletransgenic mice (Fig. 4 B). The enhanced airway eosinophilia in doxycycline-treated B6.129Il4raR576/R576/IL-13tg
mice was associated with increased detection by real-time
PCR analysis of mRNA encoding the eosinophil chemotactic factor Ccl11 (eotaxin; Fig. 4 C). In contrast, transcripts of
other chemokines such as Ccl2 were not significantly affected
(Fig. 4 D). The capacity of the R576 mutation to up-regulate
IL-13–induced Ccl11 expression in the airways was mirrored in studies on primary cell cultures of several lineages
involved in allergic airway inflammation. Both IL-4– and
IL-13–induced Ccl11 expression was increased in bone marrow–derived macrophages (BMDMs) and lung fibroblasts
derived from R576 mutant mice as compared with WT
controls (Fig. 4 E). Collectively, these results established that
the R576 substitution heightened IL-13–induced allergic
airway inflammation and tissue eosinophilia irrespective of
the genetic background of the mice tested.

Figure 3. The Q576R substitution promotes airway hyperreactivity, airway eosinophilia, and goblet cell metaplasia after IL-13 administration. (A) WT BALB/c mice (Q576; genotype Il4ra Q576/Q576) and C.129.Il4ra R576/R576 (R576) mutant mice (n = 14–15 mice per group) were tested for their
enhanced pause (Penh) response, a proxy measure of AHR, to aerosolized methacholine at 96 h after three daily intranasal instillations of IL-13 or BSA (5 µg
each). Group responses were analyzed by repeated measures ANOVA (P < 0.001, R576/IL-13 vs. Q576/IL-13 groups). (B) Eosinophil count in BAL fluid.
(C) PAS staining of IL-13–treated lung tissue. Arrowheads represent PAS+ goblet cells. (D) Enumeration of PAS-positive goblet cells. Values represent
means ± SEM derived from three to four independent experiments. **, P < 0.01; ***, P < 0.001. Bar, 100 µm.
2194
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the R576 mutation could augment IL-13–induced airway
inflammation, C.129.Il4ra R576/R576 and WT BALB/c control mice were subjected to daily instillations of recombinant IL-13 or vehicle alone (BSA) for three consecutive
days and compared for the magnitude of their responses.
For both genotypes, the IL-13–challenged mice developed
an allergic inflammatory response characterized by AHR to
methacholine, eosinophilic infiltration, and goblet cell
hyperplasia. (Fig. 3, A–D). However, for each of these parameters the C.129.Il4ra R576/R576 mice exhibited an enhanced
response as compared with WT BALB/c control mice, indicating that the R576 substitution augmented the IL-13–induced
airway inflammation.
These results were validated in a second IL-13–dependent
allergic airway inflammatory model that used a doxycyclineresponsive IL-13 transgene (tg) driven by the Clara cell–
specific promoter CC10 and maintained on a C57BL/6
background. Double-transgenic B6.129Il4raR576/R576/IL-13tg
mice were derived and compared with single-transgenic
B6.Il4raQ576/Q576/IL-13tg mice for allergic airway inflammation both in the absence of and upon treatment with doxycycline for a total of 7 d. Both sets of mice exhibited basal
airway eosinophilia and goblet cell metaplasia as compared
with their respective IL-13tg-negative controls, a reflection
of the leaky nature of the IL-13tg (Fig. 4 A; Zheng et al.,
2000). Importantly however, the B6.129Il4raR576/R576/IL-13tg
double-transgenic mice exhibited increased basal airway
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Expression profiling revealed that the induction by doxycycline of IL-13tg expression resulted in the up-regulation of
related sets of canonical IL-13–responsive genes in the B6.
Il4raQ576/Q576/IL-13tg and B6.129Il4raR576/R576/IL-13tg mice
as compared with their respective control groups (Tables
S1 and S2). Comparison of the gene sets up-regulated by the
IL-13tg revealed several asthma-related genes that met a
rather restrictive criterion for selection (a twofold change
cutoff in expression) on the R576 but not the Q576 background (Tables S3 and S4). A more direct comparison of
the magnitude of gene expression in doxycycline-treated
B6.129Il4raR576/R576/IL-13tg versus B6.Il4raQ576/Q576/IL-13tg
mice, done at a more inclusive 1.2-fold change cutoff, continued to reveal enhanced expression of several IL-13–responsive
genes in the homozygous R576 allele group as compared
with their Q576 counterparts (Fig. 5 A and Table S5). These
included genes involved in airway inflammation and remodeling such as Retnlb (resistin-like ) and Alox15 (15 lipoxygenase; Chu et al., 2002; Mishra et al., 2007), goblet cell
metaplasia (Clca3 and Clca1) (Nakanishi et al., 2001), mucin
and mucin granule components (Muc5b and Gp2), regulators

Figure 4. The Q576R substitution promotes IL-13tg–induced airway eosinophilia and goblet cell metaplasia. (A and B) B6.Il4raQ576/Q576,
B6.129Il4raR576/R576, B6.Il4raQ576/Q576/IL-13tg single-, and B6.129Il4raR576/R576/IL-13tg double-transgenic mice (n = 10–17 per group) were treated for 1 wk with
doxycycline. The mice were then analyzed for BAL fluid eosinophilia (A) and goblet cell metaplasia by PAS staining (B). Horizontal bars in A represent means.
(C and D) Real-time PCR analysis of Ccl11 (C) and Ccl2 (D) mRNA levels in total lung extracts of sham- and doxycycline-treated mice (n = 8–14 per group).
(E) Real-time PCR analysis of Ccl11 expression in IL-4– and IL-13–treated BMDMs, lung fibroblasts, and airway epithelial cells (n = 4–14 per group). Values
represent means ± SEM derived from 3–4 independent experiments (A–D) and 4–14 independent experiments (E). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
JEM VOL. 206, September 28, 2009
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The R576 allele up-regulates a subset
of IL-13–responsive genes
To determine potential mechanisms underlying the trophic
effects of the R576 allele on airway inflammation and remodeling, we first compared the gene expression profile in the
lungs of doxycycline-treated B6.129Il4raR576/R576/IL-13tg
mice versus B6.129Il4raR576/R576 littermates that lacked the
IL-13tg (n = 11 and 5, respectively). We similarly compared the
gene expression profile in the lungs of doxycycline-treated
B6.Il4raQ576/Q576/IL-13tg mice versus tg-negative littermates
(n = 8 and 5, respectively). Lastly, we directly compared
the gene expression profiles in the doxycycline-treated
B6.129Il4raR576/R576/IL-13tg versus B6.Il4raQ576/Q576/IL-13tg
mice. Experimentally, total RNA was isolated, and then
amplified and hybridized on Affymetrix 430 2.0 chips. Only
those gene probe comparisons that were statistically significant
(P < 0.05) were considered valid. Results were also compared
with other published gene expression profiles in IL-13 and
allergen-induced allergic airway inflammation (Zimmermann
et al., 2003, 2004, 2005; Kuperman et al., 2005; Follettie
et al., 2006).

Published September 21, 2009

The R576 mutation promotes IL-4 production by Th2 cells
and IgE responses
To determine whether the R576 substitution influenced
Th cell differentiation as a contributing factor in its promotion of allergic airway inflammation, we compared cytokine
production of T cells of C.129.Il4ra R576/R576 and control
C.129.Il4ra Q576/Q576 mice that were induced to differentiate in

vitro into Th1 or Th2 effector lymphocytes. C.129.Il4ra R576/R576
Th2 cells exhibited a significant increase in IL-4 production as compared with C.129.Il4ra Q576/Q576 Th2 cells. In contrast, production of the Th2 cytokines IL-5 and IL-13 was
not significantly different between the two populations
(Fig. 6 A). Similarly, there was no significant difference in
IFN- production between Th1 cells of the respective genotype. These results indicated that the R576 substitution selectively up-regulated IL-4 production by Th2 cells.
The impact of the Q576R polymorphism on humoral
immunity was examined by measuring the total and antigen-specific antibody responses after immunization with
OVA mixed with alum adjuvant to promote Th2-type responses (Brewer et al., 1999), or with saline/alum as immunization control. Fig. 6 B revealed that the C.129.Il4ra R576/R576
mice exhibited increased total serum concentrations of
IgE after immunization with OVA/alum as compared with
C.129.Il4ra Q576/Q576 control mice. In contrast, IgG1 levels were
unchanged (unpublished data). Significantly, OVA-specific
antibody responses were also increased in the Q576R mutant
mice as compared with controls (Fig. 6 B). The heightened
IgE production in the Q576R mutant mice was associated
with an increased capacity of the C.129.Il4ra R576/R576 B cells
to produce IgE but not IgG1 when stimulated in vitro
with anti-CD40 mAb plus IL-4 (Fig. 6 C). Also, the R576

Figure 5. The R576 substitution heightens the expression of a subset of IL-13–induced genes in the airways. (A) Differential expression of a
subset of IL-13–induced genes in doxycycline-treated (Dox) B6.129Il4raR576/R576/IL-13tg double-transgenic versus B6.Il4raQ576/Q576/IL-13tg single-transgenic mice (n = 11 and 8, respectively). Results depict mean fold change values scoring P < 0.05 by the Student’s unpaired two-tailed t test. (B) Selected
results from A were normalized for gene expression levels in doxycycline-treated, IL-13tg–negative B6.129Il4raR576/R576, and B6.Il4raQ576/Q576 littermate
controls, respectively (n = 5 for each control group). (C) Real-time PCR analysis of Alox15, Retnlb, and Sprr2a mRNA levels in total lung extracts of doxycycline-treated and IL-13tg–negative and –positive Q576 and R576 mice (n = 4–11 per group). Values represent means ± SEM derived from two to four
independent experiments. *, P < 0.05; and **, P < 0.01 for doxycycline-treated R576/IL-13tg versus Q576/IL-13tg groups.
2196
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of ion transport (Fxyd3 and Fxyd4) (Geering, 2006), protease
and protease inhibitors (Adam8 and Timp4) (King et al., 2004),
and epithelial barrier formation (Sprr2a; Zimmermann et al.,
2005; Segre, 2006). When normalized for gene expression
in the respective control groups, several IL-13–responsive
genes persisted in being overexpressed in doxycycline-treated
B6.129Il4raR576/R576/IL-13tg as compared with similarly treated
B6.129Il4raQ576/Q576/IL-13tg mice, including Adra2a, Alox15,
Clca3, Fxyd4, Gp2, Muc5b, and Sprr2a (Fig. 5 B). The results
of the gene array studies were further validated by real-time
PCR analysis, which confirmed the up-regulation by the
R576 substitution of several IL-13–induced genes, including
Alox15, Retnlb, and Sprr2a (Fig. 5 C). These results established that the R576 substitution differentially up-regulated
the transcription of a subset of IL-13–responsive genes, especially ones involved in mucus secretion and airway inflammation and remodeling.
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substitution did not affect the up-regulation by IL-4 of CD23
and the MHC class II antigen expression in B cells, which
proceeds in a STAT-6–dependent manner (Fig. 6 D; Kaplan
et al., 1996; Shimoda et al., 1996).

JEM VOL. 206, September 28, 2009

The R576 substitution does not augment proximal
STAT6 activation
To elucidate signaling mechanisms by which the R576 substitution mediates its proallergic inflammatory effects, we examined the capacity of the R576 mutation to augment the
activation of STAT6 in different cell types in response to
IL-4 and IL-13. Results revealed that the R576 substitution
did not augment the increase in STAT6 phosphorylation in
response to IL-4 in T or B cells, nor did it alter the time
course of STAT6 dephosphorylation in both cell types upon
the cessation of IL-4 treatment (Fig. 7, A–C). Because T and
B cells express the type I but not type II IL-4R and, as such,
do not respond to IL-13, we examined STAT6 activation in
response to IL-4 and IL-13 in BMDMs, which express both
the type I and II IL-4Rs. There were no differences in the
induction of STAT6 phosphorylation, or in its dephosphorylation upon signal termination, between WT and R576
mutant BMDMs treated with IL-4 or IL-13 (Fig. 7, D–F and
G–I, respectively). These results established that the R576
substitution did not directly affect STAT6 activation in T and
B lymphocytes or BMDMs.
We also examined the activation of several pathways
downstream of IL-4R that have been previously implicated
in receptor signaling. The R576 substitution was not associated with enhanced Shc phosphorylation, nor was it associated with enhanced activation of the PI3-kinase–Akt pathway,
suggesting that the association at the I4R motif and the subsequent activation of the adaptor IRS2, which lies upstream
of PI3-kinase–Akt, was similarly unperturbed (Fig. S3).
To further determine the role of STAT6 in the up-regulation of allergic airway inflammation in the R576 mutant
mice, we examined the induction of goblet cell metaplasia and
tissue eosinophilia in doxycycline-treated WT and mutant
mice that harbor the CC10-driven IL-13tg and are either
STAT6 sufficient or deficient. Goblet cells and eosinophils
were detected by tissue staining with anti-MUC5AC and
anti-eosinophil major basic protein 1 (MBP1) antibodies, respectively. Results revealed that although doxycycline-/
IL-13tg–induced goblet cell metaplasia was increased in the
R576 mutant mice as compared with the Q576 control mice,
concurrent STAT6 deficiency abrogated goblet cell metaplasia in both mouse strains (Fig. 8, A and B). STAT6 deficiency
reduced tissue eosinophilia induced by doxycylcine/IL-13tg
2197
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Figure 6. The R576 substitution enhances IL-4 production by
Th2 cells and IgE responses in vivo. (A) Cytokine production by Th
cells. Naive WT and R576 splenic T cells (n = 12 mice per group) were
differentiated into Th1 or Th2 cells, and stimulated with anti-TCR mAB
for 48 h. Culture supernatants were examined for IL-4 and IFN- production by ELISA. (B) Total and OVA-specific serum IgE levels in Q576R
and WT control mice (n = 13 per group) after i.p. immunization with
OVA/alum. Horizontal bars represent means. (C) IgE and IgG1 production
by purified splenic B cells of Q576R and WT control mice (n = 6 per
group) stimulated in vitro for 1 wk with anti-CD40 mAb+ increasing
concentrations of IL-4. (D) Up-regulation of CD23 and I-Ad expression in
WT and R576 B cells treated with increasing concentrations of IL-4 (n =
3 per group). Values represent means ± SEM derived from two to four
independent experiments. MFI, mean fluorescence intensity. **, P < 0.01;
***, P < 0.001; and †, P < 0.05 by repeat measures two-way ANOVA.

We also examined the impact of the R576 substitution
on the induction in BMDMs of the STAT6-dependent genes
arginase 1 (Arg1) and chitinase (Chi3l3) and of arginase enzymatic
activity (Gordon, 2003; Munitz et al., 2008; Ramalingam et al.,
2008). Although the R576 substitution augmented Ccl11
gene expression in BMDMs (Fig. 4), it did not influence the
induction of Arg1 and Chi3l3 transcripts nor the expression
of arginase enzymatic activity in BMDM cells treated with
IL-4 or IL-13 (Fig. S2). Collectively, these results established
that the R576 substitution selectively augmented some IL-4R–
dependent responses in T and B cells and in BMDMs but
not others.
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back to background levels in Q576 control mice. In contrast,
the STAT6-deficient R576 mutant mice continued to exhibit significantly increased eosinophil infiltration, reaching
up to 50% of that observed in STAT6-sufficient R576 mutant
mice (Fig. 8, C and D). The residual, STAT6-independent
tissue eosinophilia in the triple-transgenic B6.Il4raR576/R576/
STAT6//IL-13tg+ mice involved a Ccl11- and Alox15independent mechanism, as the increased Ccl11 and Alox15
expression induced by the IL-13tg was abolished in both WT
and mutant mice by concurrent STAT6 deficiency (Fig. 8,
E and F). Hence, although the R576 mutation augmented
several STAT6-dependent responses, the promotion by R576
allele of tissue eosinophilia involved both STAT6-dependent
and -independent mechanisms.

Figure 7. The R576 substitution does not affect STAT6 activation by IL-4 or IL-13. (A) Intracellular staining of pSTAT6 in WT (Q576) and mutant
R576 B cells stimulated for 15 min at 37°C with 10 ng/ml IL-4. (B and C) Flow cytometric analysis of pSTAT6 induction in WT and mutant R576 B cells (B)
or T cells (C) treated with increasing concentrations of IL-4. (D–I) Flow cytometric analysis of pSTAT6 induction in BMDMs. (D and G) Intracellular staining
of pSTAT6 in BMDMs treated with IL-4 (D) or IL-13 (G). (E and H) pSTAT6 induction at increasing concentrations of IL-4 (E) or IL-13 (H). (F and I) Decay of
pSTAT6 signal upon cessation of IL-4 and IL-13 treatment. Cells were treated for 10 min with 10 ng/ml IL-4 or 100 ng/ml IL-13, and washed (arrow) and
analyzed at different time points thereafter for pSTAT6 content. Results represent means ± SEM of lymphocytes, and BMDM cultures from three to five
mice per group from two to three independent experiments. MFI, mean fluorescence intensity.
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Activation of alternative signaling pathways
by the R576 substitution
To determine potential alternative mechanisms by which the
R576 substitution promoted allergic airway inflammation,
we examined the activation of other pathways downstream

of IL-4R that have been previously implicated in receptor
signaling. Induction of IL-13tg expression by doxycycline
treatment was associated with enhanced MAPK phosphorylation in lung extracts of B6.129Il4raR576/R576/IL-13tg mice
as compared with similarly treated B6.129.Il4ra R576/R576/
IL-13tg controls (Fig. S3 A). Similarly, treatment of primary
cultures of tracheal airway epithelial cells (TECs) revealed
that IL-4 treatment of C.129.Il4ra R576/R576 cells was associated with enhanced Erk1/2 kinase activation (Fig. S3 B). IL-4
(and IL-13) treatment of C.129.Il4ra R576/R576 TEC cultures
was not associated with enhanced Shc phosphorylation, suggesting that the enhancement of MAPK activation proceeded
by a distinct mechanism (Fig. S3 B and not depicted). Treatment of TEC cultures with IL-4 resulted in increased expression of Ccl11 transcripts, with a twofold superinduction noted
in mutant C.129.Il4ra R576/R576 TECs as compared with
C.129.Il4ra Q576/Q576 controls. This differential induction of
Ccl11 transcripts in mutant TEC cells was sensitive to inhibition by the MAPK inhibitor PD98059 (Fig. S3 C). Activation of other downstream kinases, including AKT and p38
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MAPK, appeared unaffected by the R576 substitution (unpublished data). Collectively, these findings identified enhanced MAPK activation as one putative effector mechanism
of the IL-4R R576 substitution.
DISCUSSION
Several factors restrict the interpretation of association studies
examining the role of genetic polymorphisms in the pathogenesis of allergic diseases, including asthma. These include
the genetic heterogeneity of outbred human populations,
which results in confounding genetic influences from other

disease susceptibility and modifier loci. In addition, the polymorphisms under study might be but markers in linkage disequilibrium with other true disease susceptibility loci. Finally,
any particular polymorphism may influence only selective aspects of a complex phenotype such as asthma. In the present
study, we have addressed some of these restrictions as they
apply to the IL-4R Q576R polymorphism by studying the
functional impact of this polymorphism in the context of the
mouse receptor, in which the Q576 residue and the motif
within which it is embedded are conserved. By comparing
the functional attributes of the WT and the R576 mutant
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Figure 8. STAT6-dependent and -independent effects of the R576 substitution. (A and B) Induction of MUC5AC expression in airway epithelial
cells. (A) IL-13tg+ B6.Il4raQ576/Q576 and B6.129Il4raR576/R576 mice, and tg-negative controls, that were either STAT6 sufficient or deficient were examined by
immunofluorescence staining for expression of MUC5AC after doxycycline (Dox) treatment (red-staining cells). (B) MUC5AC+ cells (red-staining cells; A)
were counted and expressed as the percentage of total airway epithelial cells (DAPI [blue]-staining nuclei) in the respective airways. (C and D) Lung tissue
eosinophilia. (C) Mouse groups as in A were treated with doxycycline, and their lungs were stained with anti-eosinophil MBP1 antibodies (red-staining
cells). (D) MBP1+ cells were counted and expressed as mean cell numbers per 20× objective field (n = 10 fields per group). (E and F) Real-time PCR analysis
of Ccl11 and Alox15 expression in the different mouse groups treated with doxycycline. Values represent means ± SEM of 4–15 mice per group derived
from three to five independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars, 100 µm.
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increased proximal STAT6 activation may be best explained
by the activation by the R576 substitution of an alternative
signaling mechanism that acts in synergy with STAT6 in a
gene- and tissue-specific manner. This conclusion is supported by the finding that the enhanced eosinophil accumulation in lung tissues of Il4raR576/R576/IL-13tg+ mice proceeds
in part by STAT6-independent mechanisms (Fig. 8). Increased MAPK activation was observed in lung tissues of
Il4raR576/R576/IL-13tg+ mice and in cultured Il4raR576/R576
primary TECs, indicating that this may represent one such
mechanism (Duan et al., 2005; Lee et al., 2006). However,
the precise mechanisms by which the R576 alter signaling
via the IL-4R, and the role of MAPK and other signaling
pathways in mediating the effects of the R576 substitution,
remains to be fully established.
Earlier studies have linked the R576 substitution to
altered binding at Y575 with increased association with SHP-1
and SHP-2 (Hershey et al., 1997; Kruse et al., 2002). More
detailed analysis revealed that recombinant SHP-1 protein
selectively binds to the ITIM at positions Y713 and Y709 in
the human and mouse receptors, respectively. Mutagenesis of
the ITIM in vivo was associated with enhanced STAT6
phosphorylation, grossly elevated baseline serum IgE levels,
and exaggerated total and antigen-specific IgE responses upon
antigen sensitization (unpublished data). These findings indicated that the effects of the R576 substitution are distinct
from those associated with disruption of a bona fide ITIM.
Epidemiological surveys have linked different IL-4R
polymorphisms to distinct phenotypes of atopy and asthma.
In particular, the R576 allele has been linked to severe asthma
and low lung function in asthmatics. Other alleles such as the
cysteine 431 arginine (C431R) have been linked to atopy,
whereas the E400A has been linked to both severe asthma
and atopy (Ober et al., 2000; Wenzel et al., 2007). Furthermore, the linkage to both asthma and atopy appears to be
strengthened when analysis involves combinatorial haplotypes of different IL-4R polymorphisms, indicative of interaction among the alleles (Ober et al., 2000; Risma et al.,
2002; Hytönen et al., 2004). These findings are consistent
with some of the IL-4R polymorphisms acting by distinct
though possibly overlapping mechanisms to promote atopy
and asthma. It would be important to decipher the molecular
mechanisms underlying these interactions, as they are likely
to reflect on the different clinical phenotypes associated with
asthma, including disease progression and severity.
Previous analysis has indicated that the association of the
R576 polymorphism with severe asthma is independent of
the racial group analyzed (Wenzel et al., 2007). However, the
R576 polymorphism exists at a much higher prevalence among
individuals of African and African-American descent, groups
that suffer disproportionately from complications of asthma
(Caggana et al., 1999; Ober et al., 2000; Wu et al., 2001;
Mannino et al., 2002; Akinbami and Schoendorf, 2002). Although some of the disparity could be attributed to environmental and social factors, a substantial genetic contribution
exists (Barnes et al., 2007). Furthermore, ethnicity-specific
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alleles on a homogenous genetic background, we have identified a role for this polymorphism in promoting atopic responses and allergic airway inflammation and remodeling.
The R576 allele potentiated allergic airway inflammation
in an antigen-dependent (OVA sensitization) and -independent
manner (IL-13 inhalation and transgenic expression). In both
cases, the inflammation was associated with increased airway
eosinophilia, which persisted in the chronic antigen-driven
airway inflammation model. Given that airway eosinophilia
plays a critical role in unfolding the acute and chronic changes
associated with asthma, including AHR, mucous production,
and subepithelial fibrosis, the increased airway eosinophil
load would provide one mechanism by which the R576
allele promotes allergic airway inflammation (Humbles et al.,
2004; Lee et al., 2004). Gene expression profiling identified
additional mechanisms by which the R576 allele may exert
proinflammatory functions. A subset of IL-13–regulated
genes associated with airway inflammation, remodeling, and
mucus production, including Alox15, Retnlb, Clca3, and others were superinduced by the R576 allele. Although some
metabolites of 15-lipoxygenase, such as the lipoxins, may
serve an antiinflammatory function, others such as 15(S)hydroxyeicosatetraenoic acid may promote airway remodeling
(Chu et al., 2002; Kühn and O’Donnell, 2006). In addition,
expression of Clca3 is sufficient for induction of goblet cell
metaplasia in mice (Patel et al., 2006). Collectively with the
recent demonstration of the induction of subepithelial fibrosis by resistin-like , these findings point to potential targets
of intervention to interrupt the evolution of chronic airway
changes promoted by the R576 allele (Mishra et al., 2007).
The R576 allele enhanced total and antigen-specific IgE
responses, a likely reflection of both increased IL-4 production by Th2 cells and IL-4–driven isotype switching to 
heavy chain in B cells. An increased atopic response and a
heightened resident airway tissue response to IL-4 and IL-13
may both contribute to the aggressive allergic airway inflammatory phenotype of the R576 allele. However, the capacity
of the R576 allele to potentiate IL-13–induced allergic airway inflammation, which proceeds in the absence of an IgEassociated adaptive immune response, indicates that the
airway inflammatory phenotype can be uncoupled from the
atopic response. Nevertheless, it is likely that the two mechanisms interact synergistically in vivo in the context of an
antigen-driven allergic airway inflammation.
The proallergic inflammatory phenotype of the R576
allele was associated with the selective enhancement of some
STAT6-dependent responses in a tissue- and gene-specific
manner but in the absence of increased STAT6 phosphorylation on the regulatory tyrosine residue or the activation of
pathways such as PI3-kinase–Akt, Shc, or p38 MAPK. These
findings are in agreement with an earlier report that failed to
document evidence of enhanced STAT6 activation in mouse
cell lines transfected with a human IL-4R allele carrying the
R576 substitution (Wang et al., 1999).
The capacity of the R576 substitution to selectively augment some STAT6-dependent responses in the absence of
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interactions between IL-13 and IL-4R alleles have been
demonstrated for African Americans with asthma (Battle
et al., 2007). The specific contribution of the R576 allele to
asthma incidence and severity among different ethnic groups,
especially African Americans, requires further investigation.
Its association with a distinct mechanism of cellular activation
via the IL-4R suggests, however, that novel therapeutic interventions may be beneficial to asthma treatment in this and
other ethnic groups.
MATERIALS AND METHODS

Control and IL-13tg strains. The mouse Il4ra exists as two distinct
allotypes, each restricted to different strains of inbred mice, that differ at
multiple polymorphic residues (Schulte et al., 1997). The 129X1Sv/J and
C57BL/6 strains share the same allotype targeted by mutagenesis in this
study, whereas BALB/c mice carry the other. Accordingly, for studies on
the BALB/c background, the C.129.Il4raQ576/Q576 mice were used as controls except for experiments specifically indicated in the figures in which
native BALB/c mice were used. For studies on the C57BL/6 background,
native C57BL/6 mice were used as controls. The doxycycline-inducible
IL-13tg mice (CC10-rtTA–IL-13, on a C57BL/6 background; designated
in this study as B6.Il4raQ576/Q576/IL-13tg) were a gift of J. Elias (Yale University School of Medicine, New Haven, CT; Zheng et al., 2000). B6.129.
Il4raR576/R576 mice were backcrossed on the IL-13tg mice to create the
B6.129.Il4raR576/R576/IL-13tg strain.
PCR analysis. Screening of WT and mutant Il4ra alleles was performed
by PCR amplification using genomic DNA and the following primers:
common forward (F) primer, 5-TTGCAGACAATCCTGCCTA-3;
WT-specific reverse (R) primer, 5-ACTGCCTGCACAAACTCCT-3;
and mutant-specific R primer, 5-ACTGCCTGCACAAACTCTC-3.
The following primers were used for PCR screening of the residual
JEM VOL. 206, September 28, 2009

Serum total and OVA-specific IgE antibodies, in vitro IgE production,
and Th cell differentiation. These assays were performed as previously
described (Blaeser et al., 2003).
Cell preparation, stimulation, and immunoblotting. Purified T and
B cell populations were derived by magnetic bead separation (Blaeser et al.,
2000). BMDMs, primary lung fibroblast cultures, and primary air–liquid
interface cultures of mTECs were established as previously described (You
et al., 2002; Sugiura et al., 2007). Cells were serum starved for 4 h (T and
B cells) or overnight (BMDMs, fibroblasts, and mTECs) at 37°C before
stimulation with IL-4 or IL-13 at the concentrations and time periods
indicated in the figures. Immunoblotting was performed as previously
described (Blaeser et al., 2000). The following antibodies were used: antipSTAT6 and -STAT6 (Santa Cruz Biotechnology, Inc.), and anti-pAKT,
-AKT, -pERK1/2, -ERK1/2, -p38, and -p38 (Cell Signaling Technology). The blots were developed using horseradish peroxidase–conjugated
secondary antibodies and enzyme-linked chemiluminescence (ECL; GE
Healthcare).
Flow cytometry and intracellular staining. Single-cell suspensions
were stained with the antibodies indicated in the figures and analyzed on a
cytometer (FACSCalibur; BD). FITC- or PE-conjugated mAbs used were
obtained from BD and eBioscience. Intracellular staining with anti–phosphoY641–STAT6 (pSTAT6), anti–phospho–threonine 308–AKT (pAKT),
and anti–pT180/pY182 p38 MAPK (pp38) antibodies (BD) was performed
as previously described (Krutzik et al., 2004). Cell aliquots were stimulated
with IL-4 or IL-13 (PeproTech) for the periods and concentrations indicated in the figures. The cells were then fixed with 1.6% paraformaldehyde
and permeabilized for 10 min with methanol. After washing, the cells were
stained with conjugated pSTAT6, pAKT, or pp38 (Alexa Fluor 647; BD)
and analyzed by flow cytometry.
Immunofluorescence. Tissue section preparation was performed as previously described (Gomperts et al., 2007). Primary antibodies used were mouse
anti-Muc5AC mAb (1:100; Neomarkers) and 0.4 µg/ml of monoclonal rat
anti–mouse eosinophil MBP1 mAb 14.7.4 (a gift of J. Lee; Mayo Clinic
Arizona, Scottsdale, AZ). Sections were incubated with either Alexa Fluor 568
goat anti–mouse antibody (for MUC5AC staining) or biotinylated secondary
antibody for 45 min, and then with Texas red–avidin (for MBP1 staining).
After washing in PBS, all slices were stained by DAPI (Vector Laboratories)
for 2 min and mounted. All images were obtained with a fluorescent microscope (Axioskop 2 Plus; Carl Zeiss, Inc.) and a camera (AxioCam HR; Carl
Zeiss, Inc.), and imaged with a scanner (AxioVision; Carl Zeiss, Inc.) and LE
Real 4.2 software.
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Construction of targeting vector and generation of mutant mice.
Genomic DNA used to construct the targeting vector were isolated from a
bacterial artificial chromosome clone derived from the 129X1Sv/J mouse
strain that contained the mouse IL-4R gene (Genome Systems; Wrighton
et al., 1992). The replacement-type targeting vector (pKO; Lexicon) contained 13.5 kb of IL4RA sequences that extended from a XhoI site proximal
to exon 9 to a KpnI site distal to exon 12 of the gene. An AG→GA substitution was introduced by site-directed mutagenesis (QuickChange; Agilent
Technologies) into the second and third positions of codon Q576 (corresponding to bp 1964–1965 of the mouse IL-4R cDNA; Mosley et al.,
1989), changing it to R576 (CGA). The targeting construct included a floxed
neomycin resistance gene (neo) and a diphtheria toxin gene for positive/
negative selection. Targeting plasmids were transfected into RW4 ES cells
and subjected to G418 selection. Successfully targeted clones were transiently
transfected with a Cre recombinase to remove the inserted neomycin gene.
Heterozygous ES cells were injected into C57BL/6 blastocysts, and the
resultant male chimeras were mated with BALB/c females. Offspring were
screened for Hets by Southern blotting and PCR analysis. Heterozygous animals were further bred for 10 generations on BALB/c (Taconic) and
C57BL/6 (Charles River Laboratories) backgrounds to generate the congenic strains C.129Il4raR576/R576 and B6.129.Il4raR576/R576. A targeted clone
in which the floxed neo cassette was incorporated (later removed by Cre recombinase action) but which retained the WT Q576 codon was used to
generate the control C.129.Il4raQ576/Q576 congenic mouse strain. WT
BALB/c and IL-4R KO mice (BALB/c-Il4ra tm1Sz) were obtained from
Taconic and the Jackson Laboratory, respectively. All protocols were in accordance with National Institutes of Health (NIH) guidelines and approved
by the Animal Care and Use Committee at the University of California, Los
Angeles. The C.129Il4raR576/R576 strain has been deposited at the Jackson
Laboratory (strain no. 007746).

LoxP-containing allele: F, 5-GGTGTCTATTTTAGGTGCC-3, and
R, 5-TCTTCTCTCTTACTCTGTGCT-3. For RT-PCR analysis, total
RNA was extracted from splenocytes of WT and IL-4R Q576R
mutant mice using TRIzol (Invitrogen). The RNA was treated with
Dnase I to remove residual genomic DNA contamination and reverse
transcribed. Il4ra transcripts were amplified by a two-step process using
the following pairs of nested primers: outer pair F (exon 11), 5-CAG
ACCCGAAGCCAGGAGTCAACC-3, and R, (exon 12) 5-CCCTGCTTCACTGCCTGCACAAAC-3; and inner pair (both exon 12) F,
5-GAGCAGCCTTCACACCAG-3, and R, 5-ACTGCCTGCACAA
ACTCCT-3. For GAPDH transcripts, the following primers were used: F,
5-ACCACAGTCCATGCCATCAC-3, and R, 5-TCCACCACCCTGTTGCTGTA-3. For real-time PCR analysis, cDNA was reverse transcribed from 2 µg RNA per sample and used in real-time PCR assays
that used commercially available oligonucleotides and SYBR green–based
reagents (SABiosciences). The comparative Ct (threshold cycle) method
normalized to GAPDH was used to analyze relative changes in gene expression. The fold change was calculated as 2Ct for negative Ct
values (indicating a fold-change increase) and 2Ct for positive Ct
values (indicating a fold-change decrease).
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Macrophage and lung fibroblast cultures and arginase assay. BMDMs
were derived by culturing bone marrow aspirates for 7 d with M-CSF,
cultured in 24-well tissue culture plates, and stimulated with IL-4 or IL-13
at the concentrations and times indicated in the figures. The arginase assay
was performed as previously described (Ramalingam et al., 2008). Primary
lung fibroblast cultures were prepared as previously described (Sugiura
et al., 2007).

Measurement of airway tissue and functional responses. Paraffine mbedded lungs sections were stained with H&E and periodic acid–Schiff
(PAS) staining as previously described (Blaeser et al., 2003). Peribronchiolar
inflammation was graded with a score as follows: 0, normal; 1, few cells; 2, a
ring of inflammatory cells one cell layer deep; 3, a ring of inflammatory cells
two to four cells deep; and 4, a ring of inflammatory cells of greater than four
cells deep (Ford et al., 2001). Subepithelial collagen deposition was detected
by Siruis red staining (Wegmann et al., 2005). BAL was performed as previously described (Blaeser et al., 2003). Airway functional responses were examined in mice treated intranasally with either recombinant IL-13 or BSA
(5 µg/50 µl PBS for three consecutive days), and were measured at 24 h after
the last inhalation treatment using whole-body plethysmography (Buxco
Research Systems; Hamelmann et al., 1997; Blaeser et al., 2003). Responses
to increasing concentrations of aerosolized methacholine were determined
and expressed as enhanced pause (Penh) values.
Gene expression profiling. Whole-lung extracts were used to generate
total RNA, which was then amplified and used to create probes for Affymetrix 430 2.0 chips. For the analysis of gene expression measures, all Affymetrix
data were normalized using the justRMA algorithm from the Bioconductor
group (Gentleman et al., 2004). Pairwise comparisons were made for all experimental conditions such that probe sets that showed at least a 1.2–2-fold
change in expression, as specified for the respective group comparisons, were
selected for further analysis. Listed genes had to additionally show a group
mean difference above a threshold, chosen to be the 10th percentile of all
group mean differences across all probe sets. Results represent mean fold
change values derived from 5–11 independent arrays (one mouse per array)
for the respective genotype, and scoring P < 0.05 by the Student’s unpaired
two-tailed t test. Microarray data have been deposited in the Gene Expression Omnibus under accession no. 18010.
Statistical analysis. The Student’s t test, two-way analysis of variance
(ANOVA), and repeat measures two-way ANOVA with the Bonferroni
posttest analysis of groups were used to compare test groups, as appropriate.
P < 0.05 was considered statistically significant.
Online supplemental material. Fig. S1 details the derivation of Il4ra R576/R576
mutant mice. Fig. S2 shows the induction of arginase activity, and Arg1 and
Chi3l3 transcripts in IL-4– and IL-13–treated Il4ra Q576/Q576 and Il4ra R576/R576
BMDMs. Fig. S3 demonstrates the induction of MAPK activation in
Il4ra Q576/Q576 Il4ra R576/R576 mice and TECs in response to IL-13 and IL-4. Gene
expression profiles in the lungs of nontransgenic and IL-13tg Il4ra Q576/Q576
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Allergic airway inflammation models. For the acute antigen-induced
airway inflammation model, mice were sensitized and boosted with a mixture of OVA in alum, and challenged 4 wk later intranasally with 50 µg
OVA daily for three consecutive days. Control mice were sensitized and
boosted with PBS mixed with alum, and challenged with OVA. For the
chronic model, mice were immunized and boosted with OVA/alum, and
starting on week 4, challenged twice weekly with intransal OVA through
week 12. Control mice were immunized with PBS/alum challenged with
PBS. Inhaled IL-13–induced allergic airway inflammation was accomplished
by instilling 5 µg of recombinant IL-13 intranasally daily for three consecutive days. Control instillation was performed using 5 µg BSA in 50 µl PBS.
The IL-13tg–induced airway inflammation model was effected by feeding
IL-13tg+ mice and their tg-negative littermates with doxycycline-containing
chow (300 ppm; Research Diets, Inc.) for 1 wk.

Il4ra R576/R576 mice are detailed in Tables S1–S5. Online supplemental material
is available at http://www.jem.org/cgi/content/full/jem.20091480/DC1.
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